Status:
RECRUITING
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
Lead Sponsor:
Poitiers University Hospital
Conditions:
Vaccine
Streptococcus Pneumoniae
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent pneumococcal (PCV13)...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
September 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04460235
Start Date
September 7 2021
End Date
November 1 2027
Last Update
July 1 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Angers
Angers, France
2
CHU Bordeaux
Bordeaux, France
3
CHU Limoges
Limoges, France
4
Chu Nantes
Nantes, France